Quintiles also provides other services for drug makers, including offering a team of sales reps and sales educators that can help get the word out to doctors and practitioners after a drug has been approved. Pike said 27% of Quintiles' business currently stems from biotech firms, with the rest coming from larger, more established drug makers.
When asked about cancellations, Pike said those are part of the unpredictable drug business, unfortunately. However, Quintiles is not seeing cancellations ahead of what was expected.
Cramer said it should be easy to see why he's a fan of Quintiles, even if the company is, as yet, largely unknown on Wall Street.
No Huddle Offense
In his "No Huddle Offense" segment, Cramer offered up some speculation on how
might use the money it's planning on raising to increase its oil and gas production.
He said the company has already indicated it's a fan of the U.S., with its Bakken and Marcellus investments paying off big. With so much more oil being found every day in U.S. shale fields, Cramer said it's only natural to think Statoil may be on the acquisition trail.
Which company might Statoil consider buying? Cramer said
Kodiak Oil & Gas
would be two possibilities, as would
, although this company's valuation might make it prohibitive.
But Cramer said his best guess would be
, which would also be a big acquisition, but one well within reach of Statoil.
To watch replays of Cramer's video segments, visit the Mad Money page on CNBC
To sign up for Jim Cramer's free Booyah! newsletter with all of his latest articles and videos please click here.
-- Written by Scott Rutt in Washington, D.C.
To email Scott about this article, click here:
Follow Scott on Twitter
or get updates on Facebook,